MedTrace Logo

LAG3 PET Imaging in Advanced Solid Tumors

NCT04706715 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2025-05-31

No results posted yet for this study

Summary

This is an investigator-initiated, single-center, open-label clinical trial designed to evaluate the safety and PK of the PET tracer 89Zr-DFO-REGN3767 in patients prior to and during treatment.

Conditions

  • Metastatic Solid Tumor

Interventions

OTHER

89Zr-DFO-REGN3767

Anti-LAG-3 PET imaging tracer

DRUG

Cemiplimab

Cemiplimab 350 mg every 3 weeks with or without platinum-based chemotherapy.

Sponsors & Collaborators

Principal Investigators

  • E GE de Vries, MD, PhD · University Medical Center Groningen

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-18
Primary Completion
2025-11-30
Completion
2025-11-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04706715 on ClinicalTrials.gov